David Matthew T
Known title: Interim CEO and CFOCIK: 0001811612
David Matthew T's purchase track record
David Matthew T has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/6/2021 | CRMD | $9K | -5.8% | -37.4% | -10.2% |
| 11/17/2021 | CRMD | $5K | -17.5% | -29.0% | -16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRMD | ▼ Sell | Tax Withholding | 6,515 | $73K | 1/10/2025 | View on chart |
| CRMD | ▼ Sell | Tax Withholding | 8,648 | $71K | 1/2/2025 | View on chart |
| CRMD | ▲ Buy | Grant | 62,500 | $0 | 1/2/2025 | View on chart |
| CRMD | ▲ Buy | Grant | 50,000 | $0 | 1/12/2024 | View on chart |
| CRMD | ▼ Sell | Tax Withholding | 5,216 | $18K | 1/12/2024 | View on chart |
| CRMD | ▲ Buy | Open Market | 1,000 | $5K | 12/6/2021 | View on chart |
| CRMD | ▲ Buy | Open Market | 1,000 | $5K | 12/6/2021 | View on chart |
| CRMD | ▲ Buy | Open Market | 1,000 | $5K | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRMD: No direct news in the last week
Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.
CRMD: No direct news in the last week. Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.